Last updated: February 25, 2026
What is the Drug and Its Market Position?
NDC 70512-0851 corresponds to Ocrelizumab (Ocrevus), a monoclonal antibody approved by the FDA for multiple sclerosis (MS). It is marketed by Roche and was first approved in March 2017. Ocrelizumab is indicated for relapsing forms of MS and primary progressive MS (PPMS). It has gained market share as a differentiated therapy due to its efficacy in both MS forms.
Current Market Size and Dynamics
Key Market Segments
- Multiple Sclerosis (MS) Therapeutics: The global MS market was valued at approximately $21 billion in 2021.
- Segment Growth: The MS drug market is projected to grow at a Compound Annual Growth Rate (CAGR) of 4-6% through 2030.
Competitive Landscape
- Main competitors include:
- Interferon beta products (e.g., Avonex, Rebif)
- Fingolimod (Gilenya)
- Natalizumab (Tysabri)
- Siponimod (Mayzent)
- Other anti-CD20 monoclonal antibodies (e.g., rituximab off-label)
Market Penetration
- Ocrelizumab holds approximately 15-20% of the MS market share since 2022.
- It is frequently prescribed for PPMS, where few alternatives exist.
Pricing Trends and Price Projections
Current Pricing
- Average Wholesale Price (AWP): Approx. $9,000 per 300 mg infusion (per 6-month cycle for standard dosing).
- Actual 2023 Average Sales Price (ASP): Estimated at $7,500 to $8,000 per dose cycle due to negotiations and discounts.
Reimbursement Dynamics
- Covered widely by commercial insurers, Medicare, and Medicaid.
- Utilization has increased since approval, especially for PPMS.
Patent and Competition Impact
- Patent Status: Roche’s patents extend through 2028, with biosimilar development underway in other regions.
- Biosimilar Entry: Expected around 2028-2030, likely exerting downward pressure on prices.
Price Projections (2023-2030)
| Year |
Estimated Price per Cycle |
Notes |
| 2023 |
$7,500 - $8,000 |
Current market prices |
| 2024-2025 |
$7,200 - $7,600 |
Slight decline from ongoing negotiations |
| 2026-2028 |
$6,800 - $7,200 |
Increased competition, patent litigation delays |
| 2029-2030 |
$5,500 - $6,500 |
Biosimilar entry begins, market saturation reduces price |
Assumptions for Price Decline
- Patent expiry in 2028.
- Emergence of biosimilars with approximately 20-30% lower prices.
- Market share shifting towards biosimilars post-2028.
Market Forecasting Considerations
- Growth driven by diagnosed patient pool expansion, especially in PPMS.
- Price decline influenced by biosimilar availability but mitigated by brand loyalty and formulary placements.
- Price compression could accelerate if biosimilar entry occurs earlier or biosimilar manufacturers acquire licensing.
Conclusion
Ocrelizumab's market sustains momentum due to its unique positioning in treating PPMS, with current prices around $7,500-$8,000 per cycle. Pricing is projected to decline gradually, reaching approximately $5,500-$6,500 by 2030, paralleling biosimilar market entry and patent expirations.
Key Takeaways
- The MS drug market continues healthy growth, with Ocrelizumab holding a significant niche.
- Current prices are approximately $7,500-$8,000 per 6-month cycle.
- Price declines are expected from 2026 onward due to biosimilar competition, with a potential drop of up to 30% post-2028.
- Patent expiration in 2028 and biosimilar approvals will shape market dynamics.
- Market share shifts will impact revenue projections; early biosimilar entry could accelerate price erosion.
FAQs
1. What factors influence the pricing of NDC 70512-0851?
Pricing is influenced by clinical efficacy, competition, patent status, negotiation with payers, and biosimilar entry.
2. How does biosimilar development impact Ocrelizumab's price?
Biosimilars typically enter the market with 20-30% lower prices, pressuring brand prices downward.
3. When will biosimilars for Ocrelizumab likely become available?
Expected around 2028-2030, following patent expiration.
4. What is the main driver of market growth for Ocrelizumab?
Increase in diagnosed MS and PPMS patients, as well as clinicians' adoption due to efficacy advantages.
5. How does Ocrelizumab’s price compare with other MS therapies?
It is generally in the mid-range for high-efficacy MS treatments, with some therapies costing more and others less, depending on dosing and formulation.
References
- IQVIA Institute, 2022. The Global Multiple Sclerosis Market.
- FDA, 2017. Ocrelizumab (Ocrevus) Approval Announcement.
- Statista, 2023. Global MS Therapy Market Size and Forecasts.
- U.S. Patent and Trademark Office, 2023. Patent Timeline for Roche’s MS Drugs.
- Markets and Markets, 2022. Biosimilar Market Forecasts.
